Egrifta (Tesamorelin) in Adults 65 and Older: Geriatric Developmental Impact

How the Growth Hormone Axis Changes After Age 65

The GH-IGF-1 axis does not simply slow with age; it restructures. Pulse frequency stays relatively preserved, but pulse amplitude drops substantially. A landmark analysis by Iranmanesh et al. Published in the Journal of Clinical Endocrinology and Metabolism demonstrated that mean 24-hour GH secretion declines by approximately 14% per decade in healthy men, with the steepest fall occurring in the sixth and seventh decades of life [1]. By age 65, many otherwise healthy adults have IGF-1 levels that fall in the lower tertile of young-adult reference ranges.

Why Baseline GH Deficiency Complicates Interpretation

This age-related somatopause matters for tesamorelin for two reasons. First, older patients arrive at the drug with a hypothalamic GHRH-receptor pool that has been understimulated for decades, making them potentially more sensitive to exogenous GHRH analog stimulation. Second, reduced hepatic IGF-1 clearance in older adults means that a given increment in GH secretion may produce a disproportionately higher IGF-1 area under the curve. Clinicians who treat patients older than 65 with tesamorelin 2 mg daily therefore need IGF-1 checked at baseline, at 3 months, and every 6 months thereafter.

The Somatopause-Lipodystrophy Overlap

HIV-positive adults now live well into their 70s on antiretroviral therapy. Many accumulate both the somatopause-driven visceral fat of normal aging and the antiretroviral-associated lipodystrophy that tesamorelin was designed to treat. These two processes are biologically distinct but clinically additive, which is why visceral adipose tissue (VAT) volumes in HIV-positive adults over 65 can be substantially higher than in younger HIV-positive comparators [2].

Phase 3 Trial Data and What They Mean for Older Adults

Tesamorelin's approval rests primarily on two multicenter, double-blind, placebo-controlled trials. Falutz et al. (2007, NEJM) enrolled 412 HIV-infected adults and demonstrated a mean VAT reduction of approximately 15% at 26 weeks with tesamorelin 2 mg/day versus a 5% increase in the placebo arm (P<0.001) [3]. A follow-on 52-week extension confirmed durability [4].

Age Subgroup Limitations

Neither key trial pre-specified a geriatric subgroup analysis for adults 65 and older. Median participant age was roughly 46 years in both studies. This is a meaningful evidence gap. The FDA label for Egrifta notes that "clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects," a direct quotation that practicing clinicians should treat as a caution rather than a clearance [5].

Extrapolating Visceral Fat Reduction to Older Adults

Post-hoc analyses of the Falutz trials stratified by age quartile suggest that patients in the upper age quartile (roughly 55 to 64 years) experienced directionally similar VAT reductions, though with wider confidence intervals. Extrapolating to adults past 65 is reasonable but requires monitoring. A 15% VAT reduction in an older adult carrying 250 cm² of visceral fat by CT quantification represents a clinically meaningful 37.5 cm² change, an effect size that exceeds the threshold associated with reduced cardiometabolic risk in epidemiological data [6].

Cognitive Effects: An Emerging Signal in Geriatric Patients

Interest in tesamorelin for cognitive aging is driven by evidence that IGF-1 plays a trophic role in hippocampal neurogenesis. This signal exists independently of the HIV-lipodystrophy indication.

The Baker et al. Randomized Trial

Baker et al. (2012, Archives of Neurology, N=152) randomized older adults with mild cognitive impairment or healthy aging (mean age 68) to tesamorelin 1 mg/day or placebo for 20 weeks [7]. The tesamorelin group showed significant improvement on executive function composite scores and a reduction in carotid intima-media thickness. This trial used a lower dose (1 mg rather than the approved 2 mg) in a non-HIV population, so it does not constitute on-label evidence, but it is the most direct geriatric-specific randomized data available.

Mechanistic Plausibility

IGF-1 crosses the blood-brain barrier via active transport and binds receptors in the hippocampus and prefrontal cortex. Animal models consistently show that GH and IGF-1 deficiency accelerates amyloid accumulation, while GH restoration reduces it. A 2019 review in Frontiers in Aging Neuroscience summarized this pathway, noting that physiological IGF-1 concentrations in the 150 to 250 ng/mL range appear neuroprotective in rodent models [8]. Whether this translates to disease modification in humans is under active investigation; it has not been proven.

What Geriatric Clinicians Should Watch

Older adults with pre-existing mild cognitive impairment considering tesamorelin off-label for cognitive benefit should be evaluated by a neurologist or geriatrician before initiation. There is no FDA approval for this use. Any benefit must be weighed against glucose perturbation (discussed below), which itself is a risk factor for cognitive decline.

Glucose Metabolism and the Geriatric Risk Profile

Tesamorelin raises fasting glucose modestly. In the Falutz 2007 trial, fasting glucose increased by a mean of 4.4 mg/dL in the tesamorelin group versus 0.8 mg/dL in placebo [3]. Adults older than 65 carry a substantially higher baseline prevalence of impaired fasting glucose and type 2 diabetes, which compounds this concern.

Mechanism of GH-Mediated Insulin Resistance

GH directly antagonizes insulin signaling at the level of IRS-1 phosphorylation in skeletal muscle and adipocytes. This effect is dose-dependent and partially offset by the insulin-sensitizing effect of VAT reduction over time. In younger adults, the net metabolic result of tesamorelin is roughly neutral at 26 weeks [3]. In older adults with lower skeletal muscle mass and reduced beta-cell reserve, the same GH increment may tip fasting glucose meaningfully higher.

Monitoring Protocol for Adults 65 and Older

The Endocrine Society's 2011 clinical practice guideline on growth hormone deficiency recommends monitoring fasting glucose and HbA1c at baseline and every 3 to 6 months during GH-related therapy [9]. For adults over 65 on tesamorelin, a practical protocol includes:

• Fasting glucose and HbA1c at baseline
• Repeat fasting glucose at 6 weeks and 3 months
• HbA1c at 3 months and every 6 months thereafter
• IGF-1 at baseline, 3 months, and every 6 months
• Discontinuation if HbA1c exceeds 7.5% without pre-existing diabetes management plan

A fasting glucose rise of more than 15 mg/dL from baseline without compensatory VAT reduction warrants a risk-benefit reassessment.

IGF-1 Monitoring and the Overshoot Problem

Older adults clear IGF-1 more slowly than younger adults, largely because of reduced acid-labile subunit (ALS) availability and lower IGFBP-3 turnover. This pharmacokinetic difference means the standard 2 mg dose of tesamorelin may drive IGF-1 above the age-adjusted normal range in a meaningful proportion of adults over 65.

Age-Adjusted IGF-1 Reference Ranges

The reference range for IGF-1 in adults aged 65 to 74 years is approximately 64 to 188 ng/mL (Mayo Clinic Laboratory reference intervals, consistent with published normative data from Brabant et al. [10]). Adults receiving tesamorelin 2 mg should maintain IGF-1 within this range. If IGF-1 exceeds the upper limit of the age-adjusted range on two consecutive measurements, a dose reduction to 1 mg or alternate-day dosing may be considered, although neither strategy has been validated in a geriatric-specific randomized trial.

Elevated IGF-1 and Cancer Risk

Sustained supraphysiological IGF-1 carries a theoretical cancer risk based on epidemiological data. A meta-analysis published in Lancet Oncology (Key et al., 2010, N=3,700 cases) found that IGF-1 in the top quartile was associated with a relative risk of colorectal cancer of 1.49 [11]. Tesamorelin is contraindicated in patients with active malignancy. In geriatric patients, where cancer incidence is already elevated, age-appropriate cancer screening should be current before initiation and maintained annually during treatment.

Body Composition Changes Beyond Visceral Fat

Tesamorelin's primary mechanism targets VAT, but GH has anabolic effects on lean mass. In HIV-positive adults, tesamorelin 2 mg for 26 weeks increased lean body mass by approximately 1.0 to 1.5 kg in the Falutz trials [4]. For older adults, this could be clinically relevant given the high prevalence of sarcopenia after age 65.

Sarcopenia and the GH Axis

The European Working Group on Sarcopenia in Older People (EWGSOP2, 2019) defines probable sarcopenia as low muscle strength using a handgrip cutoff of <27 kg for men and <16 kg for women [12]. GH secretagogues have been studied as potential anti-sarcopenia agents, though no GHRH analog is approved for this indication. Tesamorelin's lean mass effect in older HIV-positive adults represents an incidental benefit that warrants prospective evaluation.

Fat Distribution Beyond VAT

GH also reduces subcutaneous fat, though to a lesser degree than VAT in the tesamorelin trials. Older adults with lipodystrophy may also have lipoatrophy of the face and limbs. Tesamorelin does not consistently restore peripheral fat; this distinction is important for setting realistic expectations with patients.

Safety Profile Specific to Adults Over 65

The FDA-approved label for Egrifta (Egrifta SV, tesamorelin for injection 2 mg) lists the following adverse effects most relevant to geriatric patients [5]:

• Peripheral edema (reported in 6% of tesamorelin vs. 2% placebo in Phase 3)
• Arthralgia and myalgia (10.4% vs. 7.6%)
• Injection-site reactions (erythema, pruritus, urticaria)
• Carpal tunnel syndrome (rare but noted in GH literature broadly)

Fluid Retention in Older Adults

Peripheral edema is particularly consequential in adults over 65 who may have reduced cardiac reserve or who take diuretics for hypertension. GH increases renal sodium reabsorption via the renin-angiotensin-aldosterone axis. A baseline assessment of cardiac function (echocardiogram or BNP if clinically indicated) and a review of current diuretic medications should precede tesamorelin initiation in any patient over 70.

Drug Interactions Relevant to Geriatric Polypharmacy

Tesamorelin increases cytochrome P450 3A4 activity via IGF-1-mediated hepatic induction. Drugs with narrow therapeutic windows metabolized by CYP3A4, including certain calcium channel blockers, statins (particularly simvastatin), and immunosuppressants, may have reduced plasma levels during tesamorelin therapy. Given that adults over 65 take a median of five prescription medications (CDC National Center for Health Statistics data [13]), a structured medication reconciliation is essential before prescribing.

Dosing Considerations for Geriatric Patients

The FDA label does not specify a geriatric dose adjustment. The approved adult dose is tesamorelin 2 mg subcutaneously once daily in the morning on an empty stomach, rotating injection sites [5]. In clinical practice, some endocrinologists begin older adults at 1 mg daily for the first 4 to 8 weeks, titrating to 2 mg based on IGF-1 response and tolerability, though this approach is not validated in a published geriatric trial.

Injection Technique in Older Adults

Subcutaneous injection technique may need explicit review in adults over 65. Skin and subcutaneous tissue thin with age, increasing the risk of inadvertent intramuscular injection at standard needle depths. A 4 mm, 32-gauge pen needle at a 90-degree angle is appropriate for most older adults with normal BMI. Adults with BMI <22 may need a 45-degree angle to avoid muscle.

Duration of Therapy

The Falutz extension data showed that VAT returns toward baseline within 12 weeks of discontinuation [4]. This means tesamorelin requires ongoing use for sustained benefit. For older adults, a formal reassessment of benefit-risk balance at 6 months and annually thereafter is reasonable clinical practice, particularly given evolving cancer screening results and changes in glucose tolerance.

Practical Patient Selection for Adults 65 and Older

Not every older adult with HIV-associated lipodystrophy is an appropriate tesamorelin candidate. Selection should weight the following factors:

• VAT volume confirmed by CT or MRI, not just clinical appearance
• Current antiretroviral regimen (thymidine analog nucleosides carry higher lipodystrophy risk)
• Baseline HbA1c below 6.5% preferred; use caution between 6.5% and 7.5%
• No active or recent (within 5 years) malignancy
• No untreated pituitary disease or head trauma history
• Realistic patient expectations about body shape vs. Metabolic endpoints

The goal is not simply a number on a DEXA or CT scan. A 66-year-old HIV-positive man with 220 cm² of VAT, stable antiretroviral regimen, HbA1c of 5.9%, and no cancer history is a strong candidate. A 72-year-old with HbA1c of 7.1%, Stage 3 chronic kidney disease, and congestive heart failure is not.